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BACKGROUND: The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous
cell carcinoma of the head and neck, showed an improved progression-free and overall survival (OS) with less toxicity when
docetaxel (T) was added to cisplatin and 5-fluorouracil (PF) for induction and given before radiotherapy (RT). The impact of the
addition of docetaxel on patients’ health-related quality of life (HRQOL) and symptoms was investigated.
METHODS: HRQOL was assessed at baseline, at end of cycle 2, and 4, 6, and 9 months after completion of RT using the European
Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC QLQ
Head and Neck Cancer-Specific Module (EORTC QLQ-H&N35). The primary HRQOL scale was global HRQOL per protocol.
RESULTS: Compliance to HRQOL assessments was 97% at baseline, but dropped to 54% by 6 months. Data were analysed up to
6 months. There was a trend towards improved global HRQOL during the treatment period. At 6 months after the end of RT, global
HRQOL was higher in the TPF arm than in the PF arm, but the low compliance does not allow to draw definitive conclusions.
Swallowing and coughing problems decreased more in the TPF arm than in the PF arm at the end of cycle 2, but to a limited extent.
CONCLUSION: Induction chemotherapy with TPF before RT not only improves survival and reduces toxicity compared with PF but also
seems to improve global HRQOL in a more sustainable manner.
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Head and neck cancer mostly influences health-related quality of
life (HRQOL) in a negative manner and can induce symptoms,
which may interfere with daily life. Both disease and treatment can
affect important functions such as eating, swallowing, and
speaking, as well as the physical appearance (Michiwaki et al,
1992; Pauloski et al, 1994; Argiris et al, 2008). Acute side-effects
related to treatment of head and neck cancer may include pain,
dermatitis, mucositis, dysphagia, and anorexia (Dropkin, 1998;
Pauloski et al, 1998; Chaplin and Morton, 1999; Rosenthal et al,
2006). Some late complications, such as xerostomia, may persist
for a long time and may even be permanent, having an adverse
effect on patient HRQOL and delaying or preventing resumption of
normal activities (Nguyen et al, 2005; Bentzen and Trotti, 2007).
In addition, a local or locoregional recurrence occurring after an
intensive primary treatment has great impact on HRQOL.
We recently reported clinical results from our phase III study,
EORTC 24971/TAX 323 (Vermorken et al, 2007). In the treatment
of unresectable locoregionally advanced squamous cell carcinoma
of the head and neck (SCCHN) of the oral cavity, oropharynx,
hypopharynx, or larynx, the combination of docetaxel, cisplatin,
and 5-fluorouracil (TPF) proved to be significantly more effective
than the standard Wayne-State University cisplatin and infusional
5-fluororuacil (PF) regimen when given as induction chemo-
therapy (CT) before radiotherapy (RT) (Vermorken et al, 2007). A
total of 358 patients underwent randomisation, with 177 assigned
to the TPF group and 181 to the PF group. At a median follow-up
of 32.5 months, the median progression-free survival was 11.0
months in the TPF group and 8.2 months in the PF group (hazard
ratio for disease progression or death in the TPF group, 0.72;
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sP¼0.007). Treatment with TPF resulted in a reduction in the risk
of death of 27% (P¼0.02), with a median overall survival (OS) of
18.8 months, as compared with 14.5 months in the PF group. There
were more grade 3 or 4 events of leucopenia and neutropenia in
the TPF group and more grade 3 or 4 events of thrombocytopenia,
nausea, vomiting, stomatitis, and hearing loss in the PF group.
In this paper, we report the analysis of HRQOL and symptoms.
METHODS
Study design and treatment
This international multi-centred European Organisation for
Research and Treatment of Cancer (EORTC) study randomly
assigned patients to either the control arm with cisplatin
(100mgm
 2) administered as a 1-h IV infusion on day 1 followed
by the continuous infusion of 5-FU (1000mgm
 2 per day) from
day 1 to day 5, or the experimental arm with docetaxel (75mgm
 2)
administered as a 1-h IV infusion on day 1 followed by cisplatin
(75mgm
 2) given over 1h by IV infusion on day 1 and then
starting the continuous IV infusion of 5-FU (750mgm
 2 per day)
from day 1 to day 5. Treatment was administered every 3 weeks
(defined as one cycle) for up to four cycles, unless progressive
disease, unacceptable toxicity, or patient refusal occurred,
whatever came first. Thereafter, patients had to receive RT, which
was delivered during a 7-week period with the use of either
conventional fractionation (total dose, 66–70Gy) or accelerated or
hyperfractionated regimens (total maximum dose of 70Gy for the
accelerated regimen and 74Gy for the hyperfractionated regimen).
The majority of patients received conventional RT. All patients
were assessed by a head and neck surgeon before start of CT and
after RT. If a neck dissection was advised, it was performed
3 months after the completion of RT.
The primary end point of the study was progression-free
survival; secondary end points included response rate before and
after RT, duration of response, time to treatment failure, OS and
HRQOL. Full details of the clinical results were reported in
Vermorken et al (2007). The trial, approved by the EORTC
protocol review committee and the ethics committee of each
participating centre, was conducted in accordance with the
Helsinki Declaration. All patients provided written informed
consent before randomisation. Randomisation was done centrally
at the EORTC headquarters, Belgium, using a minimisation
technique. Randomisation was balanced according to the primary
tumour site (oral cavity, oropharynx, hypopharynx, or larynx) and
the centre.
Procedures for QOL data collection
The EORTC QOL Questionnaire C30 (EORTC QLQ-C30, version 3)
was selected as it is a robust validated tool and the one that is most
frequently used in randomised clinical trials (Aaronson et al, 1993;
Garratt et al, 2002). The EORTC QLQ-C30 measure comprises five
functioning scales: physical, role, emotional, cognitive, and social;
three symptom scales: fatigue, nausea/vomiting, and pain; six
single item scales: dyspnoea, sleep disturbance, appetite loss,
constipation, diarrhoea, and financial impact; and the Global
HRQOL scale. The items on the measures were scaled and scored
using recommended EORTC procedures, with a higher score
representing a higher level of functioning or higher level of
symptoms (Fayers et al, 1999).
In addition, given that the problems experienced by patients
with head and neck cancer may not be fully addressed by the
EORTC QLQ-C30, the EORTC Head and Neck module, the EORTC
QLQ-H&N35, with 35 items specifically developed for head and
neck patients in cancer clinical trials, was included (Bjordal et al,
2000). This measure has a structure of seven symptom scales
(pain, swallowing, senses, speech, social eating, social contact,
and sexuality), six symptom items (problems with teeth, problems
with opening mouth, dry mouth, sticky saliva, coughing,
and feeling ill), and five additional items related to the use of
painkillers, nutritional supplements and feeding tube, and changes
in body weight.
Furthermore, the clinician-assessed Performance Status Scale
for Head and Neck Cancer Patients (PSS-HN) tool, containing
three questions on eating in public, understandability of speech,
and normalcy of diet, was used, as this can provide unique
information, independent of HRQOL measures (List et al, 1996).
A validated visual analogue scale ad hoc pain thermometer was
also employed.
As per protocol, the HRQOL questionnaires had to be completed
before knowledge of treatment allocation by the patient (up to
2 weeks before randomisation), at cycle 2 just before the next cycle
(at the time of tumour assessment), at the end of CT before
starting RT (at the time of tumour assessment), and then, 6 and
9 months after completion of RT. Patients were asked to complete
the questionnaires regardless of stable or progressive disease or
relapse. Guidelines for administering questionnaires were pro-
vided, ensuring standardisation of HRQOL data by all personnel
(Young et al, 2002). The two EORTC measures were translated and
culturally validated before use in this study, in accordance with
standard EORTC practices.
Statistical analysis
HRQOL was a secondary study end point, whereas the sample size
calculation was based on assessment of the primary end point
(PFS). To reduce multiple testing, five primary domains were
preselected for this trial: global HRQOL from the EORTC
QLQ-C30, and pain, swallowing, speech, and coughing from the
EORTC QLQ-H&N35 module. On the basis of results of a phase II
study showing that patients treated with TPF had a rapid and
substantial tumour shrinkage, which may result in an improve-
ment of the local symptoms commonly reported with locally
advanced tumours (Schrijvers et al, 2004), it was anticipated that
the experimental arm (TPF) would be superior to the control arm
(PF) in lowering symptom levels. Owing to the expected higher
toxicity of the experimental arm, no significant difference in the
global score during treatment was anticipated. The remaining
HRQOL and symptom variables were then examined on an
exploratory basis. The results of this study are presented in
accordance with recent criteria for reporting HRQOL (Efficace
et al, 2003).
All analyses were performed using SAS version 9.1.3 (Licence
through EORTC), according to the intent-to-treat principle. All
patients were analysed in their assigned treatment arm.
For the purpose of the analysis, time windows for accepting
HRQOL forms were defined as follows: baseline HRQOL assess-
ments had to be obtained no more than 14 days from
randomisation and before the start of CT; HRQOL assessments
at the end of cycles 2 and 4 had to be obtained no more than
3 weeks from the end of cycle 2 or 4 and before the start of RT;
HRQOL assessments at 6 months after RT had to be obtained no
sooner than 3 months after the end of RT and no more than
7.5 months after the end of RT.
A mixed model with an undefined covariance structure was
fitted to the longitudinal HRQOL data (for each selected score) to
test for differences between the two treatment arms. All patients
with at least one valid HRQOL form were included in the analysis
(n¼353).
Using a standard established method of interpretation for the
HRQOL scores for the EORTC tool, the minimal important
difference was calculated (Osoba et al, 1998). Differences of at
least 10 points (on a 0–100 scale) were classified as the minimum
clinically meaningful change in a HRQOL parameter. For claims of
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spotential improvement in the five selected scales, the level of
statistical significance was fixed at 0.01 to reduce the risk of false-
positive findings. However, the adjustment of the P-value was only
partial, as it did not take into account multiple testing due to
multiple time points.
Given that missing data is a common problem in HRQOL
studies and could bias the results, compliance rates with per-
protocol HRQOL assessments were compared between treatment
arms, and the missingness mechanism was graphically investi-
gated. Compliance was computed as the number of received QoL
forms divided by the number of expected forms at each time point.
Expected forms were for patients still on treatment at the given
time point (i.e., for patients who started cycle 2 at the time point
‘End of cycle 2’, cycle 4 at the time point ‘End of cycle 4’, and RT at
the time point ‘At 6 months after RT’). Complementary analyses of
the proportion of patients experiencing a worsening or an
improvement of more than 10 and 20 points (respectively classified
as moderate and large effects), were performed as sensitivity
analyses (Osoba et al, 1998). As QoL scales only take a finite
number of equidistant values from 0 to 100, that is, for the Global
HRQOL scale, 0, 8.3, 16.6, 25, and so on, a worsening or an
improvement of 10 points and 20 points will correspond to a 16.6
and 25 points difference, respectively.
RESULTS
Between April 1999 and March 2002, 358 patients from 37
institutions in 15 European countries were randomised between
the TPF arm (177) and the PF arm (181). The two treatment arms
were balanced according to baseline demographic and clinical
characteristics (Vermorken et al, 2007).
HRQOL: compliance and baseline scores
QoL data from 353 patients among a total of 358 patients (99%)
were included in the analysis. Overall compliance to the QLQ-C30
questionnaire was 97% at baseline, 86% at the end of cycle 2,
and 76% at the end of cycle 4 (Table 1). Compliance was above
50% at 6 months after RT (108 patients). Because the compliance
dropped below 50% at 9 months after RT, data were analysed up to
6 months after RT. Fisher exact tests for compliance difference
between the two treatment arms revealed no significant difference
at baseline, nor at any follow-up time points (Table 1).
Although there were very few missing scores for the EORTC
QLQ-C30 questionnaire, the number of missing items for the head
and neck module was higher. Specifically, 35% of the planned
HRQOL assessments did not include the head and neck module
because at the time of the trial, validated and translated
questionnaires were not available in countries such as the Czech
Republic, Hungary, Serbia, and Slovak Republic. For the head and
neck module, no interpretation of the results was made at
6 months after RT because of the very low amount of data collected.
For each of the preselected HRQOL scales, global HRQOL, pain,
swallowing, speech, and coughing, the evolution of the mean
scores just before missingness was graphically investigated to
check the validity of the mixed model. A sharp increase or decrease
in scores just before missingness is usually a good indicator of
non-ignorable missing data. None of our analyses indicated a
possible non-ignorable missingness process.
Baseline HRQOL scores were quite similar in both treatment
arms and comparable with the reference values in head and neck
cancer patients with stage III–IV disease (Table 2) (Scott et al,
2008).
Primary HRQOL scales: between arm differences and
changes over time
Global HRQOL increased during CT in both treatment arms and
was maintained at 6 months after the end of RT in the TPF arm
while it decreased in the PF arm (Table 3, Figure 1). The mean
difference between the treatment arms at 6 months after the end of
RT was 9.5 points, very close to the clinically meaningful change of
10 points and statistically significant (P¼0.0092). However, when
analysing the change from baseline, the P-value was reduced to
0.0211, not below the statistical level of significance of 0.01.
Pain, swallowing problems, speech problems, and coughing
decreased during CT in both treatment arms (Figure 2). There
were no treatment-related differences in pain and speech
problems. Swallowing and coughing problems decreased more in
the TPF arm compared with the PF arm. The differences between
the two treatment arms did not reach the 10-point difference at any
time point. When analysing changes from baseline, no difference
was statistically significant.
Sensitivity analyses
The percentage of patients who experienced either a moderate
(410 points) or important (420 points) worsening/improvement
in each selected scale at any of the three time points (end of cycle 2,
end of cycle 4 and 6 months after the end of RT), compared with
baseline, were compared between treatment arms. These additional
analyses confirmed the overall trend towards an advantage of the
TPF arm compared with the PF arm with a higher percentage of
Table 1 Compliance with QLQ-C30assessments
Time points Forms expected Forms received Percentage Difference P-value
Baseline 358 346 96.6 0.225
TPF 177 169 95.5
PF 181 177 97.8
End of cycle 2 328 282 86.0 0.340
TPF 164 144 87.8
PF 164 138 84.2
End of cycle 4 255 193 75.7 0.545
TPF 136 105 77.2
PF 119 88 74.0
At 6 months after RT
a 198 108 54.5 0.794
TPF 112 62 55.4
PF 86 46 53.5
At 9 months after RT
a 170 76 44.7 0.443
TPF 95 40 42.1
PF 75 36 48.0
Abbreviations: QLQ-C30¼Quality of Life Questionnaire C30; TPF¼docetaxel, cisplatin, and 5-fluorouracil regimen; PF¼cisplatin and 5-fluorouracil regimen;
RT¼radiotherapy.
a6 months and 9 months after the end of radiotherapy.
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spatients experiencing an improvement and a lower percentage of
patients experiencing a worsening in global HRQOL, coughing,
and swallowing. For pain and speech problems, the percentage of
patients worsening in the TPF arm was higher, but the percentage
showing an improvement was also higher. The differences in
proportions did not exceed 10% and were not statistically
significant (Table 4).
Other HRQOL scales
An exploratory analysis of the non-preselected remaining HRQOL
scales was performed. An increase in loss of appetite was noticed
in the PF arm, whereas it was stable in the TPF arm (mean
difference of 10.3; P¼0.013 at the end of cycle 4); there was more
weight loss (mean difference of 17.1; P¼0.059) and less weight
gain (mean difference of 25.1; P¼0.0007) in the PF arm at the end
of cycle 4 (Figure 3). Except for appetite loss, the measures were
similar in the two treatment arms at 6 months after RT. For all
other scales, there were no statistically significant treatment
differences at any time point.
Analysis of the ad hoc pain thermometer data confirmed that
there was no difference in pain intensity between the two treatment
arms (data not shown). Evaluation of the clinician-assessed
PSS-HN tool showed high compliance (75% at 6 months after
RT), as these data were collected from case-report forms rather
Table 2 Baseline QoL scores and reference data (Scott et al, 2008).
Reference data; head and
neck cancer stage III–IV,
mean (s.d.)
EORTC 24971 TPF
arm (N¼169),
mean (s.d.)
EORTC 24971 PF
arm (N¼177),
mean (s.d.)
P-value for difference
between
arms
QLQ-C30
Global QoL 63.1 (22.4) 61.2 (23.3) 61.1 (20.3) 0.97
Physical functioning 81.2 (20.2) 85.7 (18.1) 88.8 (15.5) 0.09
Role functioning 78.8 (27.9) 79.2 (29.3) 84.1 (23.8) 0.09
Emotional functioning 71.2 (24.1) 70.2 (23.2) 75.0 (21.6) 0.05
Cognitive functioning 86.4 (19.1) 88.6 (17.7) 89.6 (15.8) 0.56
Social functioning 82.2 (24.7) 84.5 (23.0) 85.8 (21.8) 0.60
Fatigue 27.6 (25.0) 27.6 (25.7) 24.2 (22.7) 0.19
Nausea and vomiting 5.2 (13.3) 4.7 (12.6) 4.1 (12.7) 0.62
Pain 24.9 (26.3) 29.8 (26.4) 26.4 (23.0) 0.20
Dyspnoea 18.0 (26.6) 13.4 (22.5) 12.1 (21.5) 0.57
Insomnia 28.5 (32.4) 26.2 (29.4) 27.5 (31.0) 0.71
Appetite loss 19.4 (29.3) 22.9 (31.3) 21.6 (29.4) 0.69
Constipation 11.7 (23.2) 14.3 (24.4) 14.9 (26.5) 0.81
Diarrhoea 6.1 (16.7) 5.0 (15.8) 3.4 (10.7) 0.27
Financial difficulties 18.8 (30.2) 19.0 (29.0) 17.5 (27.6) 0.63
QLQ-HN-35
Pain 29.9 (25.1) 29.6 (24.8) 27.4 (24.4) 0.51
Swallowing 27.5 (26.1) 26.1 (26.2) 28.3 (26.6) 0.51
Senses 20.0 (30.0) 9.8 (20.3) 12.3 (21.0) 0.34
Speech 27.1 (27.2) 20.6 (24.8) 23.3 (26.9) 0.43
Social eating 23.9 (26.7) 22.4 (26.1) 27.5 (30.7) 0.17
Social contact 13.2 (19.1) 10.3 (16.0) 12.0 (17.5) 0.44
Sexuality 32.3 (36.1) 32.4 (35.5) 24.8 (33.6) 0.11
Teeth 27.8 (35.0) 24.2 (34.6) 24.3 (36.5) 0.98
Opening mouth 22.4 (31.9) 28.5 (35.6) 22.6 (33.7) 0.19
Dry mouth 31.1 (34.2) 19.0 (25.9) 20.2 (25.1) 0.72
Sticky saliva 32.4 (35.4) 26.1 (34.4) 29.1 (31.3) 0.49
Coughed 34.9 (32.1) 30.8 (25.5) 30.5 (26.2) 0.92
Felt ill 21.7 (29.2) 17.1 (26.5) 19.1 (28.1) 0.58
Pain killers 52.8 (49.9) 58.1 (49.6) 59.0 (49.4) 0.90
Nutritional supplements 27.0 (44.4) 23.7 (42.7) 27.0 (44.6) 0.57
Feeding tube 18.3 (38.7) 14.4 (35.3) 13.8 (34.6) 0.89
Weight loss 41.3 (49.2) 42.7 (49.7) 52.2 (50.2) 0.15
Weight gain 25.9 (43.8) 20.9 (40.8) 17.2 (37.9) 0.48
Abbreviations: EORTC¼European Organisation for Research and Treatment of Cancer; QOL¼quality of life; QLQ-C30¼Quality of Life Questionnaire C30;
QLQ-HN-35¼Head and Neck Cancer-Specific Module; TPF¼docetaxel, cisplatin, and 5-fluorouracil regimen; PF¼cisplatin and 5-fluorouracil regimen.
Table 3 QLQ-C30–global health status
Assessment time TPF PF Treatment difference P-value
Baseline 61.5 (s.d.¼1.69) 61.1 (s.d.¼1.64) 0.8646
End of cycle 2 69.3 (s.d.¼1.73) 66.8 (s.d.¼1.75) 0.3290
End of cycle 4 70.7 (s.d.¼1.91) 65.6 (s.d.¼2.05) 0.0695
6 Months after RT 68.9 (s.d.¼2.39) 59.4 (s.d.¼2.73) 0.0092
Abbreviations: QLQ-C30¼Quality of Life Questionnaire C30; TPF¼docetaxel, cisplatin, and 5-fluorouracil regimen; PF¼cisplatin and 5-fluorouracil regimen;
RT¼radiotherapy.
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sthan HRQOL questionnaires. This tool provides the clinician’s
rating of performance status; an outcome related to, but not
equivalent to QOL. Changes from baseline were analysed for the
three items of this tool, that is, Eating in public, Understandability
of speech, and Normalcy of diet, as an imbalance in baseline
characteristics was noticed for two of the three scales.
None of the comparison between arms for these scales reached
the statistical significance. Compared with baseline, no major
treatment differences were noted in these three scales (Figure 4).
DISCUSSION
In our randomised phase III study, HRQOL was assessed in
patients with unresectable locoregionally advanced SCCHN after
treatment with induction TPF or PF followed by RT.
The global HRQOL improved during induction CT in both
treatment arms. As expected per protocol, no difference in global
HRQOL was seen between arms during the treatment period.
Interestingly, at 6 months after the end of the RT the global QoL
remained higher than at baseline only in the TPF arm. In the PF
arm, the global HRQOL returned to baseline scores, as usually seen
in head and neck HRQOL studies (Abdel-Wahab et al, 2005;
Curran et al, 2007). This resulted in a difference between the arms
at 6 months after RT of 9.5 points, very close to a clinically
meaningful improvement. Unfortunately, the compliance was too
low to draw definite conclusions. In the pros, the compliance was
similar in both arms. The imbalance between the number of
patients still on study at this time point was mainly because of a
higher rate of treatment discontinuation in the PF arm owing to
toxicity and a higher rate of deaths owing to progressive disease,
pointing towards a possible bias in disfavour of the experimental
arm. In the cons, the analysis technique used relies on the
assumption of data missing at random (MAR), which can always
be criticised.
This trend towards an improvement in global HRQOL in the
TPF arm occurred parallel to an increase in OS, higher response
Baseline End of cycle 2 End of cycle 4 6 M after RT
Assessment time
Treatment TPF PF
80
70
60
50
40
30
Global quality of life
Means + 95% CI
Figure 1 Evolution of mean scores in global QoL over time.
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Figure 2 Evolution of mean scores in other selected scales over time.
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sTable 4 Percentage of patients experiencing worsening/improvement from baseline during the follow-up period in selected scales
TPF (N¼148) PF (N¼147) P-value for difference
N (%) N (%)
Global quality of life
a
X16.6 Points worsening 35 (23.6) 37 (25.2) 0.79
X25 Points worsening 21 (14.2) 21 (14.3) 1.00
X16.6 Points improvement 80 (54.1) 69 (46.9) 0.25
X25 Points improvement 52 (35.1) 40 (27.2) 0.17
Coughing
b
X33.3 Points worsening 19 (12.8) 24 (16.3) 0.41
X33.3 Points improvement 49 (33.1) 35 (23.8) 0.09
Pain
c
X11.1 Points worsening 29 (19.6) 21 (14.3) 0.28
X22.2 Points worsening 19 (12.8) 13 (8.8) 0.35
X11.1 Points improvement 50 (33.8) 42 (28.6) 0.38
X22.2 Points improvement 40 (27.0) 24 (16.3) 0.03
Speech problems
d
X11.1 Points worsening 34 (23.0) 24 (16.3) 0.19
X22.2 Points worsening 17 (11.5) 15 (10.2) 0.85
X11.1 Points improvement 51 (34.5) 43 (29.3) 0.38
X22.2 Points improvement 35 (23.6) 27 (18.4) 0.32
Swallowing
e
X11.1 Points worsening 18 (12.2) 27 (18.4) 0.15
X22.2 Points worsening 12 (8.1) 16 (10.9) 0.43
X11.1 Points improvement 47 (31.8) 39 (26.5) 0.37
X22.2 Points improvement 31 (20.9) 32 (21.8) 0.89
Abbreviations: TPF¼docetaxel, cisplatin, and 5-fluorouracil regimen; PF¼cisplatin and 5-fluorouracil regimen.
aGlobal QoL score may take all values from 0 to 100 distant by
8.3 points (0, 8.3, 16.6, and so on). A shift of more than 10 points means a shift of 16.6 points or more. A shift of more than 20 points means a shift of 25 points or more.
bCoughing score may take all values from 0 to 100 distant by 33.3 points (0, 33.3, 66.6, and so on).
cPain score may take all values from 0 to 100 distant by 2.8 points.
dSpeech
score may take all values from 0 to 100 distant by 5.5 points.
eSwallowing score may take all values from 0 to 100 distant by 2.8 points.
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Figure 3 Evolution of mean scores in other non-selected scales over time.
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srate, and less severe toxicity, owing to a lower dose of cisplatin and
5-FU in the TPF arm than in the PF arm (Vermorken et al, 2007).
Why HRQOL after 6 months was better in the TPF arm than in the
PF arm is not completely clear, but can probably be explained, in
part, by fewer recurrences of the tumour. Another explanation can
be the lower dose of cisplatin and 5-FU used in TPF compared with
PF. Long-term toxicity of cisplatin leads to polyneuropathy and
ototoxicity, which can influence the global QoL. Patients’ overall
HRQOL usually results from both treatment effects/side-effects
and factors linked to the disease evolution, which are often
indistinguishable.
A few investigators have assessed the longitudinal changes of
HRQOL in patients with SCCHN during treatment. The general
picture is a deterioration during the first 3 months after the start of
treatment, followed by a slow recovery (de Graeff et al, 1999;
Bairati et al, 2005; Fang et al, 2005). Locoregionally advanced
disease patients included in the randomised trial of cetuximab with
RT vs RT alone performed better in the combined arm (Bonner
et al, 2006; Curran et al, 2007) and, although there was a gain in
OS, no differences in HRQOL were observed. This study is the first
reporting HRQOL during induction CT followed by RT, showing
an improvement during the first weeks after start of neo-adjuvant
CT. However, we did not measure the QoL during or in the last
week of the RT. Thus, we can only speculate on the QoL during the
RT in the TPF and PF arm. On the one hand, it could have
been better in the TPF arm, because the trend in a better QoL,
which was seen after the CT before the start of Rt, continued to
improve, or on the other hand, it could have been worse in the TPF
arm, because docetaxel can act as a radiosensitiser (Nabell and
Spencer, 2003).
Swallowing dysfunction and aspiration are seen in a high
proportion of patients with SCCHN after combined chemo-
radiation (Bentzen and Trotti, 2007). Therefore, swallowing and
coughing, although not always related to aspiration, were selected
as primary domains for this analysis. A trend to a higher reduction
in swallowing and coughing problems was seen in the TPF arm
compared with the PF arm, but the extent of the reduction was
limited. In addition less loss of appetite was observed in the TPF
arm, whereas less weight loss and more weight gain were observed
in the TPF arm at the end of cycle 4. Eating problems may result
from both the primary location of the head and neck cancer and
treatment-induced adverse effects, such as pain in the mouth,
problems with dentition, decreased saliva, and problems swallow-
ing. Hence, weight loss is reported to affect 35–50% of patients
with SCCHN, and is known to increase morbidity and mortality
(van Bokhorst-de van der Schuer et al, 1999). Thus, the
improvement of swallowing combined with less eating problems
observed in the TPF arm is not only beneficial for HRQOL but
probably causes less morbidity and mortality in the follow-up.
Our randomised controlled trial (RCT) had several limitations.
Despite being a robust, well-designed, and monitored RCT,
HRQOL compliance became very limited over time, making only
analyses of short-term HRQOL data possible and not allowing to
draw definite conclusions. However, this is not unexpected, as
collecting data in head and neck trials can be difficult, and indeed,
the lack of RCTs with HRQOL results in the literature may support
this hypothesis. In addition, at the start of this study, not all
translations of the EORTC Head and Neck module were available,
hence reducing the amount of information available from the
module. At last, even if, as per protocol, very precise timing for
the HRQOL assessment was described, time windows need to
be defined to perform the analysis and assign HRQOL data to the
different time points and allow for some delays. A 3-week delay
was allowed for the assessments ‘At the end of cycle 2’ and ‘At the
end of cycle 4’, which may have caused a slight underestimation of
the treatment effect.
Nevertheless, there are positive points. This was a RCT with a
good sample size; a similar compliance in both arms; the use of a
robust methodology under missing data of the MAR type; and no
indication of a source of bias in the investigation of the
missingness mechanism.
At this moment, the standard treatment of locally advanced
SCCHN consists of concurrent chemoradiation. Concurrent
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Figure 4 Evolution of mean scores from the Performance Status Scale
for Head and Neck tool.
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schemoradiation was not incorporated as treatment in the EORTC
24971/TAX 323. However, at this moment, several studies are
running with TPF as induction CT followed by concurrent
chemoradiotherapy or RT combined with an inhibitor of the
epidermal growth factor receptor (EGFR). Because these treat-
ments cause more toxicity than RT without concurrent combina-
tion, an improvement of the QoL and swallowing after TPF would
be of real value.
The field of treatment of the locally advanced SCCHN is moving
quickly at this moment. The main goal of these developments is to
administer a less toxic regimen to patients while keeping the same
chance for cure. The use of intensity modulated RT (IMRT) and
the use of targeted therapies, such as EGFR inhibitors, will lead to
less toxicity and hopefully a better QoL for those patients (Feng
et al, 2010). In addition, human papillomavirus-positive patients
do have a better prognosis, both after CT and RT (Fakhry and
Gillison, 2006). In future, these patients may be treated with a less-
toxic regimen than the nowadays used concomitant chemo-
radiotherapy. The exact role in future for induction CT, that is,
TPF, in this moving field is not yet clear. However, our observation
of an improvement of global QoL during induction CT is
important, and has to be investigated in future trials with
induction CT followed by concurrent chemoradiation using IMRT,
or followed by concurrent EGFR inhibition with RT.
In summary, in unresectable SCCHN patients, TPF compared
with PF as induction CT before RT seemed to improve global
HRQOL and swallowing in parallel with a significantly
improved OS and less severe induced toxicity. These analogous
improvements of a longer life with a better HRQOL in some
areas can be seen as the ultimate goal of treatment of cancer
patients and opens the door for further studies to determine the
exact place of TPF as induction CT for the treatment of locally
advanced SCCHN.
ACKNOWLEDGEMENTS
Sanofi-Aventis financially sponsored this trial. In addition, the
QOL analysis was in part supported by Grant numbers 5U10-
CA11488-29 through to 5U10 CA11488-39 from the National
Cancer Institute (Bethesda, MD, USA), as well as by the EORTC
Charitable Trust. We thank all EORTC investigators who
participated in this study and the EORTC Headquarters staff
who worked for this study. We thank all the patients for
participating in this clinical trial to help us understand the best
way to treat this cancer. The clinical trials.gov registry number was
NCT00003888.
Author contributions: Conception and design: MEM, CC, AB;
administrative support: MEM, CC, AB; provision of study
materials or patients: all authors and investigators; collection
and assembly of data: MEM, CC, AB; data analysis and
interpretation: CMLvH, MEM, CC, AB, JB and JBV; manuscript
writing: CMLvH, MEM, AB, JBV; final approval of manuscript: all
authors.
Disclaimer: Its content is solely the responsibility of the authors
and does not necessarily represent the official views of the National
Cancer Institute
Conflict of interest
JBV is consultant for Sanofi-Aventis.
REFERENCES
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ,
Filiberti A, Flechtner H, Fleishman SB, de Haes JC (1993) The European
Organization for Research and Treatment of Cancer QLQ-C30: a quality-
of-life instrument for use in international clinical trials in oncology.
J Natl Cancer Inst 85: 365–376
Abdel-Wahab M, Abitbol A, Lewin A, Troner M, Hamilton K, Markoe A
(2005) Quality-of-life assessment after hyperfractionated radiation
therapy and 5-fluorouracil, cisplatin, and paclitaxel (Taxol) in inoperable
and/or unresectable head and neck squamous cell carcinoma. Am J Clin
Oncol 28: 359–366
Argiris A, Karamouzis MV, Raben D, Ferris RL (2008) Head and neck
cancer. Lancet 371: 1695–1709
Bairati I, Meyer F, Gelinas M, Fortin A, Nabid A, Brochet F, Mercier JP,
Tetu B, Harel F, Abdous B, Vigneault E, Vass S, Del VP, Roy J (2005)
Randomized trial of antioxidant vitamins to prevent acute adverse effects
of radiation therapy in head and neck cancer patients. J Clin Oncol 23:
5805–5813
Bentzen SM, Trotti A (2007) Evaluation of early and late toxicities in
chemoradiation trials. J Clin Oncol 25: 4096–4103
Bjordal K, de Graeff A, Fayers PM, Hammerlid E, van PC, Curran D,
Ahlner-Elmqvist M, Maher EJ, Meyza JW, Bredart A, Soderholm AL,
Arraras JJ, Feine JS, Abendstein H, Morton RP, Pignon T, Huguenin P,
Bottomly A, Kaasa S (2000) A 12 country field study of the EORTC QLQ-
C30 (version 3.0) and the head and neck cancer specific module (EORTC
QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group.
Eur J Cancer 36: 1796–1807
Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU,
Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H,
Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab
for squamous-cell carcinoma of the head and neck. N Engl J Med 354:
567–578
Chaplin JM, Morton RP (1999) A prospective, longitudinal study of pain in
head and neck cancer patients. Head Neck 21: 531–537
Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J,
Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA (2007) Quality of
life in head and neck cancer patients after treatment with high-dose
radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:
2191–2197
de Graeff A, de Leeuw RJ, Ros WJ, Hordijk GJ, Battermann JJ, Blijham GH,
Winnubst JA (1999) A prospective study on quality of life of laryngeal
cancer patients treated with radiotherapy. Head Neck 21: 291–296
Dropkin MJ (1998) Disfigurement and dysfunction with head and neck
cancer surgery. ORL Head Neck Nurs 16: 28–29
Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’haese S, Zurlo A
(2003) Beyond the development of health-related quality-of-life
(HRQOL) measures: a checklist for evaluating HRQOL outcomes in
cancer clinical trials: does HRQOL evaluation in prostate cancer research
inform clinical decision making? J Clin Oncol 21: 3502–3511
Fakhry C, Gillison ML (2006) Clinical implications of human papilloma-
virus in head and neck cancers. J Clin Oncol 24: 2606–2611
Fang FM, Tsai WL, Chien CY, Chiu HC, Wang CJ, Chen HC, Hsiung CY (2005)
Changing quality of life in patients with advanced head and neck cancer
after primary radiotherapy or chemoradiation. Oncology 68: 405–413
Fayers PM, Aaronson NK, Bjordal K (1999) EORTC QLQ-C30 Scoring
Manual 9th edn EORTC: Brussels, Belgium
Feng FY, Kim HM, Lyden TH, Haxer MJ, Worden FP, Feng M, Moyer JS,
Prince ME, Carey TE, Wolf GT, Bradford CR, Chepeha DB, Eisbruch A
(2010) Intensity-modulated chemoradiotherapy aiming to reduce dys-
phagia in patients with oropharyngeal cancer: clinical and functional
results. J Clin Oncol 28: 2732–2738
Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002) Quality of life
measurement: bibliographic study of patient assessed health outcome
measures. BMJ 324: 1417
List MA, D’Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, Vokes E
(1996) The performance status scale for head and neck cancer patients
and the functional assessment of cancer therapy-head and neck scale.
A study of utility and validity.. Cancer 77: 2294–2301
Michiwaki Y, Schmelzeisen R, Hacki T, Michi K (1992) Articulatory
function in glossectomized patients with immediate reconstruction using
a free jejunum flap. J Craniomaxillofac Surg 20: 203–210
Nabell L, Spencer S (2003) Docetaxel with concurrent radiotherapy in head
and neck cancer. Semin Oncol 30: 89–93
HRQOL in head and neck cancer patients (EORTC 24971)
CML van Herpen et al
1180
British Journal of Cancer (2010) 103(8), 1173–1181 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sN g u y e nN P ,F r a n kC ,M o l t zC C ,V o sP ,S m i t hH J ,K a r l s s o nU ,D u t t aS ,M i d y e t t
A, Barloon J, Sallah S (2005) Impact of dysphagia on quality of life after
treatment of head-and-neck cancer. I n tJR a d i a tO n c o lB i o lP h y s61: 772–778
Osoba D, Rodrigues G, Myles J, Zee B, Pater J (1998) Interpreting the
significance of changes in health-related quality-of-life scores. J Clin
Oncol 16: 139–144
Pauloski BR, Logemann JA, Rademaker AW, McConnel FM, Stein D,
Beery Q, Johnson J, Heiser MA, Cardinale S, Shedd D (1994) Speech and
swallowing function after oral and oropharyngeal resections: one-year
follow-up. Head Neck 16: 313–322
Pauloski BR, Rademaker AW, Logemann JA, Colangelo LA (1998) Speech
and swallowing in irradiated and nonirradiated postsurgical oral cancer
patients. Otolaryngol Head Neck Surg 118: 616–624
Rosenthal DI, Lewin JS, Eisbruch A (2006) Prevention and treatment of
dysphagia and aspiration after chemoradiation for head and neck cancer.
J Clin Oncol 24: 2636–2643
Schrijvers D, van HC, Kerger J, Joosens E, Van Laer C, Awada A,
van den Weyngaert D, Nguyen H, Le BBouder C, Castelijns JA,
Kaanders J, De Mulder P, Vermorken JB (2004) Docetaxel, cisplatin
and 5-fluorouracil in patients with locally advanced unresectable head
and neck cancer: a phase I-II feasibility study. Ann Oncol 15:
638–645
Scott NW, Fayers P, Bottomley A (2008) EORTC QLQ-C30 Reference Values
Manual. EORTC Quality of Life Group publications: Brussels, Belgium
van Bokhorst-de van der Schuer M, van Leeuwen PA, Kuik DJ, Klop WM,
Sauerwein HP, Snow GB, Quak JJ (1999) The impact of nutritional status
on the prognoses of patients with advanced head and neck cancer.
Cancer 86: 519–527
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M,
Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A,
Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL (2007)
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck
cancer. N Engl J Med 357: 1695–1704
Young T, de Haes H, Fayers P (2002) Guidelines for Assessing Quality of Life
in Clinical Trials 2nd edn EORTC Quality of Life Study Group
Publications: Brussels, Belgium
HRQOL in head and neck cancer patients (EORTC 24971)
CML van Herpen et al
1181
British Journal of Cancer (2010) 103(8), 1173–1181 & 2010 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
s